Skip to main content

Table 4 Analgesic use according to the experience of bone complications

From: Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

Outcome

At-risk perioda

Patient population

EU5b

N = 813

France

N = 146

Germany

N = 175

Italy

N = 173

Spain

N = 141

UK

N = 173

Patients who received analgesics by at-risk period, n (%)c

 Any analgesic use

Overall

All patients

461 (57)

102 (70)

110 (63)

84 (49)

94 (67)

66 (38)

With BCs

162 (76)

36 (90)

34 (71)

35 (71)

25 (86)

27 (63)

Without BCs

299 (50)

66 (62)

76 (60)

49 (40)

69 (62)

39 (30)

Period 2

All patients

457 (56)

104 (71)

110 (63)

84 (49)

93 (66)

60 (35)

With BCs

160 (75)

34 (85)

35 (73)

33 (67)

26 (90)

28 (65)

Without BCs

296 (49)

70 (66)

75 (59)

51 (41)

67 (60)

32 (25)

Period 3

All patients

234 (29)

43 (30)

66 (38)

46 (27)

10 (7)

32 (19)

With BCs

89 (42)

15 (38)

21 (44)

22 (45)

21 (72)

13 (30)

Without BCs

145 (24)

28 (26)

45 (35)

24 (19)

31 (28)

19 (15)

Patients who received analgesics by stepc and at-risk period, n (%)d

 Step 1

Overall

All patients

255 (31)

38 (26)

70 (40)

56 (32)

51 (36)

47 (27)

 Step 2

192 (24)

46 (32)

50 (29)

30 (17)

36 (26)

25 (15)

 Step 3

162 (20)

51 (35)

37 (21)

21 (12)

34 (24)

10 (6)

 Step 1

With BCs

73 (34)

11 (28)

18 (38)

21 (43)

9 (31)

14 (33)

 Step 2

72 (34)

15 (38)

11 (23)

16 (33)

12 (41)

16 (37)

 Step 3

72 (34)

21 (53)

18 (38)

10 (20)

12 (41)

7 (16)

 Step 1

Without BCs

182 (30)

27 (26)

52 (41)

35 (28)

42 (38)

33 (25)

 Step 2

120 (20)

31 (29)

39 (31)

14 (11)

24 (21)

9 (7)

 Step 3

89 (15)

30 (28)

19 (15)

11 (9)

22 (20)

3 (2)

 Step 1

Period 2

All patients

216 (27)

30 (21)

63 (36)

50 (29)

36 (26)

41 (24)

 Step 2

165 (20)

39 (27)

49 (28)

23 (13)

31 (22)

19 (11)

 Step 3

144 (18)

46 (32)

33 (19)

18 (10)

32 (23)

8 (5)

 Step 1

With BCs

65 (30)

8 (20)

16 (33)

18 (37)

8 (28)

16 (37)

 Step 2

62 (29)

14 (35)

12 (25)

12 (24)

9 (31)

13 (30)

 Step 3

59 (28)

16 (40)

16 (33)

7 (14)

11 (38)

6 (14)

 Step 1

Without BCs

150 (25)

22 (21)

47 (37)

32 (26)

28 (25)

25 (19)

 Step 2

102 (17)

25 (24)

37 (29)

11 (9)

22 (20)

6 (5)

 Step 3

86 (14)

30 (28)

17 (13)

11 (9)

21 (19)

2 (2)

 Step 1

Period 3

All patients

130 (16)

17 (12)

39 (22)

30 (17)

52 (37)

21 (12)

 Step 2

82 (10)

14 (10)

27 (15)

15 (9)

30 (21)

13 (8)

 Step 3

56 (7)

15 (10)

17 (10)

7 (4)

13 (9)

5 (3)

 Step 1

With BCs

40 (19)

5 (13)

9 (19)

15 (31)

7 (24)

6 (14)

 Step 2

33 (15)

3 (8)

8 (17)

8 (16)

8 (28)

8 (19)

 Step 3

33 (16)

3 (8)

8 (17)

4 (8)

7 (24)

4 (9)

 Step 1

Without BCs

90 (15)

12 (11)

30 (24)

15 (12)

23 (21)

15 (12)

 Step 2

49 (8)

11 (10)

19 (15)

7 (6)

5 (5)

5 (4)

 Step 3

23 (4)

6 (6)

9 (7)

3 (2)

3 (3)

1 (1)

  1. BCs bone complications, EU5 five European countries (France, Germany, Italy, Spain and the UK), UK United Kingdom
  2. aOverall: from multiple myeloma diagnosis to disease progression following first-line treatment; period 2: during active first-line therapy; period 3: after treatment discontinuation. Note that analgesic use was not recorded for period 1 (before initiation of induction therapy)
  3. bAggregated EU5 data have been weighted based on the multiple myeloma incidence in each country so base sizes for individual countries may not equal the EU5 total
  4. cStep on the World Health Organization analgesic ladder
  5. dExpressed as a percentage of the total number of patients, patients with BCs or patients without BCs, as indicated (patient numbers by country – EU5 with BCs: 214; EU5 without BCs: 599; France with BCs: 40; France without BCs: 106; Germany with BCs: 48; Germany without BCs: 127; Italy with BCs: 49; Italy without BCs: 124; Spain with BCs: 29; Spain without BCs: 112; UK with BCs: 43; UK without BCs: 130)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us